Abstract
Gemfibrozil is a non-halogenated derivative of fibric acid. It was synthesized in 1968 and its first administration for clinical purposes took place in 1971 (Marks 1982). Its hypolipidemic effect is primarily evident in decreasing plasma levels of triglyceride-rich lipoproteins in hypertriglyceridemic patients who do not respond to diet. Moreover, Gemfibrozil treatment is followed by an increase in high-density lipoproteins (HDL) (Brown and Goldstein 1985).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Beaumont JL, Carlson LA, Cooper GR et al. (1970) Classification of hyperlipidemias and hyperlipoproteinemias. Bull WHO 43: 891
Blum CB, Aron L, Sciacca R (1980) Radioimmunoassay studies of human apolipoprotein. Eur J Clin Invest 66: 1240
Brown MS, Goldstein JL (1985) Drugs used in the treatment of hyperlipoproteinemias. In: Goodman, Gilman (eds) The pharmacological basis of therapeutics, 7th edn. MacMillan, New York, pp 827–845
Brown WV, Baginsky ML (1972) Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 46: 375
Curry HD, Mc Conathy WJ, Fesmire JD et al. (1980) Quantitative determination of human apolipoprotein C-III by electro-immunoassay. Biochim Biophys Acta 617: 503
Glueck CJ (1983) Influence of Gemfibrozil on high density lipoproteins. Am J Cardiol 52: 31B
Havel RJ, Shore VG, Shore B et al. (1970) Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase. Circ Res 27: 595
Kashyap ML (1984) The effects of Gemfibrozil on plasma lipids and lipoproteins in man. Vasc Med 2: 16
Kaukola S, Manninen V, Malkonen M et al. (1981) Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta Med Scand 209: 69
Kesäniemi YA, Grundy SM (1984) Influence of Gemfibrozil and Clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 251: 2241
Kissebach AH, Alfarasi S, Adams PW et al. (1976) Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridemia. Effect of 2,2 dimethyl, 5 (2,5 xylyloxy) valeric acid therapy. Atherosclerosis 24: 199
Krause BR, Newton RS (1985) Apolipoprotein changes associated with the plasma lipid-regulating activity of Gemfibrozil in cholesterol-fed rats. J Lipid Res 26: 940
Krauss RM, Hebert PN, Levy RI (1973) Further observation on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res 33: 403
La Rosa JC, Levy RI, Hebert R (1970) A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 47: 57
Lewis JE (1982) Long-term use of Gemfibrozil (LOPID) in treatment of dyslipidemia. Angiology 33: 603
Lopes-Virella HF, Stone P, Ellis S et al. (1977) Cholesterol determination in high density lipoprotein separated by three different methods. Clin Chem 23: 882
Luley C, Schwartzkopff W, Wang CS et al. (1986) Gemfibrozil treatment of hypertriglyceridemic patients alters the apolipoprotein composition in VLDL and HDL and activates lipolysis. 6th Int Washington Spring Symp, Cardiovascular disease ’86, May, pp 20–23, Abstr 149
Mahley RW, Innerarity T, Bersat TP et al. (1978) Alterations in human high-density lipoproteins, with or without increased plasma cholesterol, induced by high diets in cholesterol. Lancet 2: 807
Marks J (ed) (1982) Dyslipoproteinemia. Aspects of Gemfibrozil therapy. Res Clin Forums (Kent, England) 4: 1–8
Nikkilä EA,Ylikahri R, Huttunen JK (1976) Gemfibrozil: effect on serum lipids, lipoproteins, post-heparin plasma lipase activities and glucose tolerance in primary hypertriglyceridemia. Proc R Soc Med 69 (Suppl 2): 58
Pickering JE (1983) Clinical results with Gemfibrozil. Am J Cardiol 52: 39B
Saku K, Gartside PS, Hynd BA et al. (1985) Mechanism of action of Gemfibrozil on lipoprotein metabolism. J Clin Invest 75: 1702
Samuel P (1983) Effects of Gemfibrozil on serum lipids. Am J Med 74: 23
Samuel P (1984) Efficacy of Gemfibrozil as a lipid regulator in patient population in United States. Vasc Med 2: 8
Schaefer EJ, Levy RI, Anderson DW et al. (1978) Plasma triglycerides in regulation of HDL cholesterol levels. Lancet 2: 391
Vega JL, Grundy SM (1985) Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. JAMA 253: 2398
Vergani C, Bettale G (1981) Familial hypoalphalipoproteinemia. Clin Chim Acta 114: 45
Virtamo J, Manninen V, Malkonen M (1984) A placebo controlled, rising dose, double-blind trial with Gemfibrozil in dieting patients with primary hyperlipoproteinemia. Vasc Med 2: 22
Witztum JL, Dillingham MA, Giese W et al. (1980) Normalization of triglycerides in type IV hyperlipoproteinemia fails to correct low levels of high-density-lipoprotein cholesterol. N Engl J Med 14: 907
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Giudici, G.A., Pagani, F., Selvini, C., Stefanoni, P., Di Santo, C., Vergani, C. (1987). Effects of Gemfibrozil on Lipoproteins in Patients with Dyslipoproteinemia. In: Paoletti, R., Kritchevsky, D., Holmes, W.L. (eds) Drugs Affecting Lipid Metabolism. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71702-4_67
Download citation
DOI: https://doi.org/10.1007/978-3-642-71702-4_67
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71704-8
Online ISBN: 978-3-642-71702-4
eBook Packages: Springer Book Archive